m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03183)
Name
CHIR-98023
Synonyms
CT-98014
    Click to Show/Hide
Status
Investigative
Structure
Formula
C20H16Cl2N8O2
InChI
1S/C20H16Cl2N8O2/c21-12-1-3-14(16(22)9-12)18-15(19-24-6-7-25-19)11-28-20(29-18)26-8-5-23-17-4-2-13(10-27-17)30(31)32/h1-4,6-7,9-11H,5,8H2,(H,23,27)(H,24,25)(H,26,28,29)
InChIKey
GUMBZKISKUIHJB-UHFFFAOYSA-N
PubChem CID
9847557
TTD Drug ID
D0X4CO
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Glycogen synthase kinase-3 beta (GSK-3B)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for CHIR-98023. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of CHIR-98023 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for CHIR-98023. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CHIR-98023 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). [2], [3]
References
Ref 1 Vascular Smooth Muscle FTO Promotes Aortic Dissecting Aneurysms via m6A Modification of Klf5. Front Cardiovasc Med. 2020 Nov 20;7:592550. doi: 10.3389/fcvm.2020.592550. eCollection 2020.
Ref 2 Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. doi: 10.1016/j.bmcl.2010.01.114. Epub 2010 Jan 25.
Ref 3 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.